Literature DB >> 1471743

Low immunogenicity of a Plasmodium vivax circumsporozoite protein epitope bound by a protective monoclonal antibody.

T R Jones1, L F Yuan, H A Marwoto, D M Gordon, R A Wirtz, S L Hoffman.   

Abstract

The repeat region of the Plasmodium vivax circumsporozoite (CS) protein contains 20 copies of the nine-amino acid sequence DRA A/D GQPAG. A monoclonal antibody that passively protects monkeys against sporozoite challenge recognizes a four-amino acid linear sequence AGDR included within this nonamer, but when monkeys were immunized with a vaccine, NS1(81)V20, which contains 20 copies of the nonamer, they failed to produce antibodies to AGDR. To determine if natural exposure to sporozoites induces antibodies to AGDR, we tested sera from 176 individuals from a malaria-endemic area in Flores, Indonesia. Seventy-one percent of the adults had antibodies to the P. vivax repeat region; only 18% had detectable antibodies to AGDR. None of the subjects had antibodies to the P. vivax variant repeat ANGAGNQPG. We next tested sera from six human volunteers immunized with NS1(81)V20 and found that the vaccine, despite inducing antibodies against the nonamer, as it did in the monkeys, did not induce antibodies against AGDR. To further test our ability to raise anti-AGDR antibodies using synthetic peptides, we immunized Aotus monkeys and BALB/c mice with AGDR. Sera from the mice reacted strongly with both AGDR and a recombinant protein containing the 20 copies of the nonamer. Sera from the monkeys reacted only minimally with a protein (VIVAX-1) that contains monomeric AGDR within its sequence. Sera from the mice also bound air-dried P. vivax sporozoites, while sera from the monkeys did not.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471743     DOI: 10.4269/ajtmh.1992.47.837

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  7 in total

1.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction.

Authors:  James J Moon; Heikyung Suh; Adrienne V Li; Christian F Ockenhouse; Anjali Yadava; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-12       Impact factor: 11.205

2.  Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea.

Authors:  J W Park; S H Moon; J S Yeom; K J Lim; M J Sohn; W C Jung; Y J Cho; K W Jeon; W Ju; C S Ki; M D Oh; K Choe
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

Review 3.  Malaria distribution, prevalence, drug resistance and control in Indonesia.

Authors:  Iqbal R F Elyazar; Simon I Hay; J Kevin Baird
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

4.  A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.

Authors:  Anjali Yadava; Jetsumon Sattabongkot; Michael A Washington; Lisa A Ware; Victoria Majam; Hong Zheng; Sanjai Kumar; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

5.  Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine.

Authors:  James J Moon; Heikyung Suh; Mark E Polhemus; Christian F Ockenhouse; Anjali Yadava; Darrell J Irvine
Journal:  PLoS One       Date:  2012-02-06       Impact factor: 3.240

6.  Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein.

Authors:  Erwan Atcheson; Arturo Reyes-Sandoval
Journal:  Vaccine       Date:  2020-05-08       Impact factor: 3.641

Review 7.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.